BridgeMD
New treatment option for Breast Cancer
Official title Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity
ClinicalTrials.gov ID: NCT07070765
What this study is testing
What is Sodium-glucose transport-2 (SGLT-2) inhibitors?
Sodium-glucose transport-2 (SGLT-2) inhibitors is an investigational medicine, given as an once-daily, being studied as a potential treatment for breast cancer.
Also referred to as Dapagliflozin 10mg in addition to standard clinical care.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines. It has been suggested that sodium-glucose transporter-2 (SGLT2) inhibitors may reduce the damage to the heart caused by anthracycline chemotherapy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70, women only
You may be able to join if
- Patients with breast cancer between 18-70 years of age.
- Patients with low to medium cardiovascular risk.
- Patients scheduled for adjuvant or neo-adjuvant anthracycline therapy.
- Patients who are able to give written informed consent to take part in the study.
- Patients who can read and understand English. The current thresholds for defining cardiovascular risk for patients undergoing anthracycline...
You likely can't join if
- Patients with a known intolerance of dapagliflozin
- Patients with high cardiovascular risk as specified by the most recent cardio-oncology guidelines.
- Patients with significant renal impairment (estimated glomerular filtration rate \<45 mL/min/1.73 m2).
- Patients with a previous cancer diagnosis.
- Patients with known type 1 or 2 diabetes mellitus. We will not actively screen for diabetes. This is not done in clinical practice and there have...
- Patients with a contraindication to magnetic resonance imaging.
See the full eligibility criteria
- Patients with breast cancer between 18-70 years of age.
- Patients with low to medium cardiovascular risk.
- Patients scheduled for adjuvant or neo-adjuvant anthracycline therapy.
- Patients who are able to give written informed consent to take part in the study.
- Patients who can read and understand English. The current thresholds for defining cardiovascular risk for patients undergoing anthracycline chemotherapy are as follows: normal resting 12-lead electrocardiogram, plasma...
- Patients with a known intolerance of dapagliflozin
- Patients with high cardiovascular risk as specified by the most recent cardio-oncology guidelines.
- Patients with significant renal impairment (estimated glomerular filtration rate \<45 mL/min/1.73 m2).
- Patients with a previous cancer diagnosis.
- Patients with known type 1 or 2 diabetes mellitus. We will not actively screen for diabetes. This is not done in clinical practice and there have been no issues.
- Patients with a contraindication to magnetic resonance imaging.
- Patients with prior exposure to anthracyclines.
- Patients who cannot read and understand English.
- Patients who are pregnant
The study team makes the final eligibility decision.
Where it's taking place
- Aberdeen, Aberdeenshire, United Kingdom
- Aberdeen, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aberdeen, Aberdeenshire, United Kingdom; Aberdeen, United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.